ABBOTT LABORATORIES — Director's Dealing 2023

Jul 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-06-30

Reporting Person: Morrone Louis H. (EXECUTIVE VICE PRESIDENT)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-30	Common shares without par value	A	1815	—	Acquired	55471	Direct
2023-07-01	Common shares without par value	F	556	$109.02	Disposed	54915	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-30	Option (right to buy)	$108.52	A	7100	Acquired	2033-06-29	Common Shares (7100)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	2481	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2023.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,366 on June 30, 2024, 2,367 on June 30, 2025, and 2,367 on June 30, 2026.